Compare LARK & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LARK | EQ |
|---|---|---|
| Founded | 1885 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.5M | 157.4M |
| IPO Year | 2001 | 2018 |
| Metric | LARK | EQ |
|---|---|---|
| Price | $31.77 | $2.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 6.9K | ★ 650.9K |
| Earning Date | 04-29-2026 | 05-25-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | ★ 35.84 | N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | N/A | ★ $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $38.69 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.57 | $0.76 |
| 52 Week High | $32.39 | $3.54 |
| Indicator | LARK | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 62.66 | 34.48 |
| Support Level | $25.23 | $1.68 |
| Resistance Level | $32.38 | $2.61 |
| Average True Range (ATR) | 0.62 | 0.19 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 87.75 | 2.63 |
Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and Southwest Kansas.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.